Naturally-Occurring Invasive Urothelial Carcinoma in Dogs, a Unique Model to Drive Advances in Managing Muscle Invasive Bladder Cancer in Humans

There is a great need to improve the outlook for people facing urinary bladder cancer, especially for patients with invasive urothelial carcinoma (InvUC) which is lethal in 50% of cases. Improved outcomes for patients with InvUC could come from advances on several fronts including emerging immunotherapies, targeted therapies, and new drug combinations; selection of patients most likely to respond to a given treatment based on molecular subtypes, immune signatures, and other characteristics; and prevention, early detection, and early intervention. Progress on all of these fronts will require clinically relevant animal models for translational research. The animal model(s) should possess key features that drive success or failure of cancer drugs in humans including tumor heterogeneity, genetic-epigenetic crosstalk, immune cell responsiveness, invasive and metastatic behavior, and molecular subtypes (e.g., luminal, basal). Experimental animal models, while essential in bladder cancer research, do not possess these collective features to accurately predict outcomes in humans. These key features, however, are present in naturally-occurring InvUC in pet dogs. Canine InvUC closely mimics muscle-invasive bladder cancer in humans in cellular and molecular features, molecular subtypes, immune response patterns, biological behavior (sites and frequency of metastasis), and response to therapy. Thus, dogs can offer a highly relevant animal model to complement other models in research for ...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research

Related Links:

We present a patient diagnosed with metastatic urothelial carcinoma who progressed while on cisplatin/gemcitabine chemotherapy in the form of oligometastasis to the bone. He has achieved a durable complete response with atezolizumab.
Source: Urology Case Reports - Category: Urology & Nephrology Source Type: research
Condition:   Bladder Cancer Intervention:   Other: No intervantion on patients. retrospective study is performed on paraffin embedded tumor tissue specimens routinely collected during TURBT. Sponsor:   Istituto Clinico Humanitas Recruiting
Source: - Category: Research Source Type: clinical trials
Publication date: Available online 17 January 2020Source: European UrologyAuthor(s): Andrea Necchi, Russell Madison, Daniele Raggi, Joseph M. Jacob, Gennady Bratslavsky, Oleg Shapiro, Julia A. Elvin, Jo-Anne Vergilio, Jonathan K. Killian, Nhu Ngo, Shakti Ramkissoon, Eric Severson, Amanda C. Hemmerich, Richard Huang, Siraj M. Ali, Jon H. Chung, Prasanth Reddy, Vincent A. Miller, Alexa B. Schrock, Laurie M. GayAbstractBackgroundIn patients with rare histologies of bladder cancer, including adenocarcinoma of the bladder (ACB) and squamous-cell carcinoma (SCC), there are limited standard therapy options, defining an unmet medi...
Source: European Urology - Category: Urology & Nephrology Source Type: research
Bladder cancer is the most common cancer of the urinary system and its treatment has scarcely progressed for nearly 30 years. Advances in checkpoint inhibitor research have seemingly provided a new approach for treatment. However, there have been issues predicting immunotherapeutic biomarkers and identifying new therapeutic targets. We downloaded the gene expression profile and clinical data of 408 cases bladder urinary cancer from the Cancer Genome Atlas (TCGA) portal, and the abundance ratio of immune cells for each sample was obtained via the “Cell Type Identification by Estimating Relative Subsets of RNA Transcri...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Conditions:   Bladder Urothelial Carcinoma;   Stage III Bladder Cancer AJCC v8;   Stage IIIA Bladder Cancer AJCC v8;   Stage IIIB Bladder Cancer AJCC v8 Interventions:   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Biological: Durvalumab;   Drug: Fluorouracil;   Drug: Gemcitabine;   Drug: Gemcitabine Hydrochloride;   Drug: Methotrexate;   Drug: Mitomycin;  ...
Source: - Category: Research Source Type: clinical trials
More News: Bladder Cancer | Cancer | Cancer & Oncology | Carcinoma | Genetics | Immunotherapy | Molecular Biology | Scotland Health